Other functions analysis of anti-cancer chemicals and pharmaceutical formulations

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200722001C
Awardee
Awarding agency
Obligated
$3,571,686

Award facts

Opportunity
  • N02CM6703665 Solicitation number
Contract value 14% obligated
  • $8,672,259.37 Current, with exercised options
  • $25,543,276.37 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Kansas City, MO 64110, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 16 · Modified to remove funding per 12/17/15 email that all funding must be removed from LOC contracts. -$4,314
Funding Only Action 17 · Modified to add fee owed to contractor $282
Other Administrative Action 15 $0
Other Administrative Action 14 $0
Change Order 13 $0
Supplemental Agreement for work within scope 12 $0
Other Administrative Action 11 $0
Other Administrative Action 10 $0
Other Administrative Action 9 $0
Funding Only Action 8 $9,800
Funding Only Action 7 $50,000
Funding Only Action 6 $17,687
Supplemental Agreement for work within scope 5 $1,340,000
Other Administrative Action 4 $0
Funding Only Action 3 $150,812
Exercise an Option 2 · Analysis of anti-cancer chemicals and pharmaceutical formulations $814,303
Modification $596,699
Original award 1 $596,699
Show all 18

About this award

Written by GovTribe AI ·

This is a $25,543,276.37 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the not-for-profit research organization Mriglobal (doing business as Midwest Research Institute). The contract is for the analysis of anti-cancer chemicals and pharmaceutical formulations.

Mriglobal is a highly experienced federal contractor, holding several significant indefinite-delivery/indefinite-quantity (IDIQ) contracts with NIH, CDC, and BARDA to provide a range of specialized scientific and technical services in support of public health and national security programs, including pre-clinical evaluation of infectious disease countermeasures, chemistry/manufacturing/controls for drug development, and biological animal model/medical countermeasure development. The contract does not have a set-aside designation.

Quick answers

Who was awarded contract HHSN261200722001C?

HHSN261200722001C was awarded to Mriglobal by National Cancer Institute (National Institutes of Health) on June 1, 2007.

How much is contract HHSN261200722001C worth?

The government has obligated $3,571,686 on HHSN261200722001C. Its current value, with exercised options, is $8,672,259. Its potential value, with all options, is $25,543,276.

Was contract HHSN261200722001C competed?

The extent of competition for HHSN261200722001C was full and open competition. The government received 4 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login